Societal CDMO, Inc. (REPH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2023)

FII

1.37%

Held by 4 FIIs

DII

90.75%

Held by 15 DIIs

Promoter

0.00%

How big is Societal CDMO, Inc.?

22-Jun-2025

As of Apr 09, Societal CDMO, Inc. has a market capitalization of 116.26 million and reported net sales of 94.64 million with a net profit of -13.27 million over the last four quarters. The company has shareholder's funds of 58.66 million and total assets of 153.47 million as of Dec 23.

What does Societal CDMO, Inc. do?

22-Jun-2025

Societal CDMO, Inc. is a clinical-stage specialty pharmaceutical company focused on developing non-opioid treatments for serious acute pain. As of December 2023, it reported net sales of $28 million and a market cap of $116.26 million.

Who are in the management team of Societal CDMO, Inc.?

22-Jun-2025

As of March 2022, the management team of Societal CDMO, Inc. includes Independent Chairman Wayne Weisman, President and CEO J. David Enloe, and Independent Directors William Ashton, Michael Berelowitz, Winston Churchill, and Bryan Reasons. They oversee the company's strategic direction and operations.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

USD 116 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

5,338.60%

Debt Equity

0.51

Return on Equity

-18.45%

Price to Book

1.98

Revenue and Profits:

Net Sales:

28 Million

(Quarterly Results - Dec 2023)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

181.33%

6 Months

150.57%

1 Year

2.8%

2 Years

-34.91%

3 Years

-66.26%

4 Years

-87.57%

5 Years

-85.14%

Societal CDMO, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.78%

EBIT Growth (5y)

14.56%

EBIT to Interest (avg)

-0.14

Debt to EBITDA (avg)

14.89

Net Debt to Equity (avg)

0.51

Sales to Capital Employed (avg)

0.75

Tax Ratio

1.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

69.25%

ROCE (avg)

0.14%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.98

EV to EBIT

-130.45

EV to EBITDA

18.80

EV to Capital Employed

1.65

EV to Sales

1.55

PEG Ratio

Dividend Yield

5338.60%

ROCE (Latest)

-1.26%

ROE (Latest)

-18.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 10 Schemes (7.87%)

Foreign Institutions

Held by 4 Foreign Institutions (1.37%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 17.37% vs 8.26% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 82.61% vs -43.75% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.70",
          "val2": "23.60",
          "chgp": "17.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.90",
          "val2": "0.50",
          "chgp": "1,080.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "2.90",
          "chgp": "-10.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-4.60",
          "chgp": "82.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "128.60%",
          "val2": "-74.50%",
          "chgp": "20.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 4.88% vs 19.63% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 33.17% vs -74.56% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.60",
          "val2": "90.20",
          "chgp": "4.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.10",
          "val2": "8.60",
          "chgp": "-17.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.00",
          "val2": "14.10",
          "chgp": "-29.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "-5.00",
          "chgp": "64.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.30",
          "val2": "-19.90",
          "chgp": "33.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.60%",
          "val2": "3.10%",
          "chgp": "-2.17%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Dec'23

Sep'23

Change(%)

Net Sales

27.70

23.60

17.37%

Operating Profit (PBDIT) excl Other Income

5.90

0.50

1,080.00%

Interest

2.60

2.90

-10.34%

Exceptional Items

-1.80

0.00

Consolidate Net Profit

-0.80

-4.60

82.61%

Operating Profit Margin (Excl OI)

128.60%

-74.50%

20.31%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2023 is 17.37% vs 8.26% in Sep 2023

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is 82.61% vs -43.75% in Sep 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

94.60

90.20

4.88%

Operating Profit (PBDIT) excl Other Income

7.10

8.60

-17.44%

Interest

10.00

14.10

-29.08%

Exceptional Items

-1.80

-5.00

64.00%

Consolidate Net Profit

-13.30

-19.90

33.17%

Operating Profit Margin (Excl OI)

-18.60%

3.10%

-2.17%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 4.88% vs 19.63% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 33.17% vs -74.56% in Dec 2022

All Annual Results

Company CV

About Societal CDMO, Inc.

Societal CDMO, Inc.

Pharmaceuticals: Major

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Company Coordinates

Company Details

490 Lapp Rd , MALVERN PA : 19355-1212

Tel: 1 484 39524001 212 6001902

https://recropharma.com/

Registrar Details

Societal CDMO, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Societal CDMO, Inc.?

Watch in Real-Time

What does Societal CDMO, Inc. do?

Who are in the management team of Societal CDMO, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'23

About Societal CDMO, Inc.

Company Coordinates